clinical trial · NCT06057402
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Pfizer·phase4·recruiting·n = 80
Multiple MyelomaElranatamab
brief summary
This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.
started
Oct 3, 2023
primary completion
Feb 22, 2032
completion
Feb 22, 2032
last updated
Apr 16, 2026
detailed description
This is a single-arm elranatamab post-trial access study. Participants will receive elranatamab. All participants will receive elranatamab until disease progression, unacceptable toxicity, withdrawal of consent, study termination or, elranatamab becomes commercially accessible in the participant's country.
official title
ELRANATAMAB POST TRIAL ACCESS: AN OPEN-LABEL, SINGLE-ARM STUDY FOR PARTICIPANTS WITH MULTIPLE MYELOMA CONTINUING FROM PFIZER-SPONSORED ELRANATAMAB CLINICAL STUDIES
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol